+Compare
EYPT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
272.88M

EYPT EyePoint Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of ophthalmic pharmaceuticals

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EYPT with price predictions
08:00 PM EDT Oct 02, 2023

EYPT in downward trend: 10-day moving average moved below 50-day moving average on September 06, 2023

The 10-day moving average for EYPT crossed bearishly below the 50-day moving average on September 06, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on EYPT as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

EYPT moved below its 50-day moving average on September 12, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EYPT entered a downward trend on September 28, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EYPT's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EYPT advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

EYPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EYPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.766) is normal, around the industry mean (22.791). P/E Ratio (0.000) is within average values for comparable stocks, (131.379). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.084). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (7.825) is also within normal values, averaging (309.467).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 403.32B. NVO holds the highest valuation in this group at 403.32B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 21%. BNOX experienced the highest price growth at 337%, while RGMP experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 139% and the average quarterly volume growth was 150%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

EYPT is expected to report earnings to rise 13.33% to -69 cents per share on November 01

EyePoint Pharmaceuticals EYPT Stock Earnings Reports
Q3'23
Est.
$-0.69
Q2'23
Beat
by $0.08
Q1'23
Beat
by $0.11
Q4'22
Missed
by $0.55
Q3'22
Beat
by $0.14
The last earnings report on August 02 showed earnings per share of -61 cents, beating the estimate of -68 cents. With 192.46K shares outstanding, the current market capitalization sits at 272.88M.
A.I. Advisor
published General Information

General Information

a developer of ophthalmic pharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
480 Pleasant Street
Phone
+1 617 926-5000
Employees
144
Web
https://www.eyepointpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BOPAX26.09N/A
N/A
Sterling Capital Special Opps A
JTQAX12.38-0.16
-1.28%
JHancock ESG International Equity A
MRCGX26.56-0.35
-1.30%
Meridian Growth C
CWSGX11.25-0.19
-1.66%
Carillon Chartwell Small Cap Growth Fund
IGRFX27.84-0.51
-1.80%
Delaware Ivy Mid Cap Growth R6

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with SRNEQ. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then SRNEQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+3.08%
SRNEQ - EYPT
38%
Loosely correlated
-2.11%
AKRO - EYPT
37%
Loosely correlated
+3.68%
ORMP - EYPT
35%
Loosely correlated
-7.78%
ALXO - EYPT
35%
Loosely correlated
+56.13%
AGEN - EYPT
34%
Loosely correlated
-1.90%
More

Groups containing EYPT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+3.08%
pharmaceuticals
(undefined stocks)
32%
Poorly correlated
-0.52%
ophthalmology
(undefined stocks)
17%
Poorly correlated
+0.31%